Almotriptan - CAS 154323-57-6
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Almotriptan
Catalog Number:
154323-57-6
Synonyms:
N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine Almotriptan 154323-57-6 Almogran Almotrintan LAS-31416 UNII-1O4XL5SN61 Almotriptan (USAN) CHEBI:520985 Spectrum_001884
CAS Number:
154323-57-6
Description:
Almotriptan, also called as Almogran, is a agonist with high and specific affinity for 5-HT1B/1D receptors. developed by Almirall Prodesfarma for the acute treatment of migraine with or without aura. Besides, it acts very selectively at human cranial vess
Molecular Weight:
335.46
Molecular Formula:
C17H25N3O2S
Quantity:
Grams-Kilos
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3
InChI:
1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3
InChIKey:
WKEMJKQOLOHJLZ-UHFFFAOYSA-N
Targets:
5-HT Receptor
Chemical Structure
CAS 154323-57-6 Almotriptan

Related 5-HT Receptor Products


CAS 112885-41-3 Mosapride

Mosapride
(CAS: 112885-41-3)

Mosapride, a selective agonist of 5-HT4 receptor, could be used as a astroprokinetic agent. It is also found to be a 5-HT3 receptor antagonist.

CAS 10457-90-6 Bromperidol

Bromperidol
(CAS: 10457-90-6)

Bromperidol, a derivative of butyrophenone, is an antipsychotic commonly used in the treatment of schizophrenia as it could bind to the D2 dopamine and 5-HT2A s...

CAS 143322-58-1 Eletriptan

Eletriptan
(CAS: 143322-58-1)

Eletriptan is Serotonin 1D receptor agonist originated by Pfizer. It is a second generation triptan drug. It is used as an abortive medication, blocking a migra...

CAS 30123-17-2 Tianeptine sodium

Tianeptine sodium
(CAS: 30123-17-2)

Tianeptine sodium is a selective serotonin reuptake enhancer (SSRE), used for treating major depressive episodes.

CAS 182349-12-8 Rupatadine Fumarate

Rupatadine Fumarate
(CAS: 182349-12-8)

Rupatadine inhibits both platelet-activating factor (PAF) and histamine (H1) effects through its interaction with specific receptors.

CAS 844903-58-8 GSK163090

GSK163090
(CAS: 844903-58-8)

GSK163090 is Potent, selective, and orally active 5-HT1A/B/D receptor antagonist.

CAS 521-78-8 Trimipramine Maleate

Trimipramine Maleate
(CAS: 521-78-8)

Trimipramine Maleate is a tricyclic antidepressant for the treatment of depression and depression accompanied by anxiety.

CAS 163521-12-8 Vilazodone

Vilazodone
(CAS: 163521-12-8)

Vilazodone (EMD 68843; SB 659746A) is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evalu...

Naronapride
(CAS: 860174-12-5)

Naronapride is a selective 5-HT(4) receptor agonist for gastrointestinal motility disorders. It can accelerate overall colonic transit and tend to accelerate GE...

CAS 112885-42-4 Mosapride Citrate

Mosapride Citrate
(CAS: 112885-42-4)

Mosapride Citrate is a gastroprokinetic agent that acts as a selective 5HT4 agonist.

Tedatioxetine
(CAS: 508233-95-2)

Tedatioxetine is an antidepressant agent. It acts as a triple reuptake inhibitor and 5-HT2A, 5-HT2C, 5-HT3 and α1A-adrenergic receptor antagonist. It was discov...

CAS 58-39-9 Perphenazine

Perphenazine
(CAS: 58-39-9)

Perphenazine is a typical antipsychotic. a piperazinyl phenothiazine, used to treat psychosis

CAS 106266-06-2 Risperidone

Risperidone
(CAS: 106266-06-2)

Risperidone is a mutil-targeted antagonist for dopamine, serotonin, adrenergic and histamine receptors, used to treat schizophrenia and bipolar disorder.

CAS 112457-95-1 Tandospirone citrate

Tandospirone citrate
(CAS: 112457-95-1)

The citrate salt form of tandospirone, a partial 5HT1A receptors agonist, could be effective as an antianxiety and antidepressant agent.

CAS 170381-16-5 Zicronapine

Zicronapine
(CAS: 170381-16-5)

Zicronapine, an inden derivative, has been found to be neurotransmitter receptor modulators of sorts of neurotransmitter and was studied against Schizophrenia.

Revexepride
(CAS: 219984-49-3)

Revexepride, also referred as SSP-002358, is a very selective and potent 5-HT4 receptor agonist and a novel prokinetic that stimulates gastrointestinal motility...

CAS 209481-24-3 SB 271046 Hydrochloride

SB 271046 Hydrochloride
(CAS: 209481-24-3)

SB 271046 Hydrochloride is the hydrochloride salt form of SB 271046. SB 271046 is an orally-available and selective antagonist of the serotonin (5-hydroxytrypta...

CAS 24276-84-4 Ferulic acid sodium

Ferulic acid sodium
(CAS: 24276-84-4)

Ferulic acid sodium is one of the most abundant phenolic acids ubiquitously existing in plants. Free ferulic acid is a good antioxidant since it forms a resonan...

CAS 199864-87-4 RS 127445

RS 127445
(CAS: 199864-87-4)

RS 127445 is a high affinity, orally bioavailable, selective serotonin antagonist of 5-HT2B receptor (pIC50= 10.4) with 1000 fold selectivity over the human rec...

CAS 3200-06-4 Nafronyl oxalate

Nafronyl oxalate
(CAS: 3200-06-4)

Naftidrofuryl, being useful in enhancing cellular oxidative, could be used as a vasodilator in the treatment of peripheral and cerebral vascular disorders.

Reference Reading


1.The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies.
Marmura MJ1, Silberstein SD, Schwedt TJ. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499.
The study aims to provide an updated assessment of the evidence for individual pharmacological therapies for acute migraine treatment. Pharmacological therapy is frequently required for acutely treating migraine attacks. The American Academy of Neurology Guidelines published in 2000 summarized the available evidence relating to the efficacy of acute migraine medications. This review, conducted by the members of the Guidelines Section of the American Headache Society, is an updated assessment of evidence for the migraine acute medications. A standardized literature search was performed to identify articles related to acute migraine treatment that were published between 1998 and 2013. The American Academy of Neurology Guidelines Development procedures were followed. Two authors reviewed each abstract resulting from the search and determined whether the full manuscript qualified for review. Two reviewers studied each qualifying full manuscript for its level of evidence.
2.Efficacy of frovatriptan as compared to other triptans in migraine with aura.
Evers S1, Savi L, Omboni S, Lisotto C, Zanchin G, Pinessi L. J Headache Pain. 2015;16:514. doi: 10.1186/s10194-015-0514-8. Epub 2015 Apr 1.
BACKGROUND: The treatment of migraine attacks with aura by triptans is difficult since triptans most probably are not efficacious when taken during the aura phase. Moreover, there are insufficient data from randomised studies whether triptans are efficacious in migraine attacks with aura when taken during the headache phase. In this metaanalysis, we aimed to compare the efficacy of frovatriptan versus rizatriptan, zolmitriptan, and almotriptan.
3.Gellan gum-based mucoadhesive microspheres of almotriptan for nasal administration: Formulation optimization using factorial design, characterization, and in vitro evaluation.
Abbas Z1, Marihal S1. J Pharm Bioallied Sci. 2014 Oct;6(4):267-77. doi: 10.4103/0975-7406.142959.
BACKGROUND: Almotriptan malate (ALM), indicated for the treatment of migraine in adults is not a drug candidate feasible to be administered through the oral route during the attack due to its associated symptoms such as nausea and vomiting. This obviates an alternative dosage form and nasal drug delivery is a good substitute to oral and parenteral administration.
4.The therapeutic armamentarium in migraine is quite elderly.
Martelletti P1. Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):175-7. doi: 10.1517/17425255.2015.982089. Epub 2014 Dec 1.
Global Burden of Disease 2010 study considers migraine as one of the most important noncommunicable diseases in the world, classifying it third in terms of global prevalence (14.70%): it sums up the 54.19% of all the years of life lived with disabilities caused by the rest of all neurological disorders. This Editorial provides an historical excursus of old and new-entry molecules in migraine therapeutic area. Drugs for acute treatment such as triptans date back to the early 1990s with the appearance of sumatriptan and the following six triptans in the years immediately after (zolmitriptan, rizatriptan, naratriptan, eletriptan, almotriptan, frovatriptan). Prophylaxis drugs, dedicated to patients with medium/high frequency of crises, show as last entries topiramate and botulinum toxin type A. The use of this preventative group, with its intrinsic limits, is mandatory to reduce the risk of migraine chronification, a highly harmful clinical phenomenon that produces as its natural consequence the medication overuse headache.